Compass Therapeutics, Inc. (NASDAQ: CMPX) is a Healthcare company (Biotechnology) with a market capitalization of $109M. The Maz Rating grades it against the other companies in its sector.
Compass Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $0.61, Compass Therapeutics, Inc. trades at 0.8x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -49.9%, return on invested capital of -62.0% and a free cash flow yield of -56.6%. On the balance sheet: a debt-to-equity ratio of 0.06 and a current ratio of 6.79. Over the past 52 weeks the share price ranged from $0.57 to $6.88, with a beta of 0.91.
Compass Therapeutics, Inc. does not currently pay a dividend.
17 Wall Street analyst ratings cover the stock: 16 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Compass Therapeutics, Inc. (CMPX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 62.8% / 30% · Interest income / Revenue 162900000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 62.8% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 162900000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 62.8% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 162900000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 2.18% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 94.6% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 162900000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 93.4% / 33.33% · (Cash+Recv) / Total Assets 93.4% / 33.33% · Interest income / Revenue 162900000.0% / 5% | Fail |
No. As of September 2026, Compass Therapeutics, Inc. (CMPX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Compass Therapeutics, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 162900000.0% of each dividend: Compass Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.